COI.
search Request for Consideration arrow_forward menu
close Submit Innovation
close
92
Waltham, MA, USA Series B / Partnership Scale

RNA-Targeted Small Molecule Therapeutics

Arrakis Therapeutics • Led by ["Jennifer Petter","Michael Gilman"]

🔒 Confidential
COI SCORE 92 VERIFIED

🔬 The Innovation Core

The Pain Point

85% of disease-causing proteins are 'undruggable' by traditional methods because they lack binding pockets. Targeting the RNA that makes the protein is a solution, but RNA was thought to be too unstable/floppy to drug.

The Solution

A platform that freezes RNA into stable 'tertiary structures' (shapes) and identifies 'pockets' where small molecules can bind. This allows patients to take a pill to stop a disease-causing protein from ever being made.

⚡ Verified Impact

● Validated
CERTIFICATION

Prototype

TRL 5/9

📊 Market Traction

Revenue History ($M)

Market Share

🧠 Analyst Verdict: Category Creator

"Arrakis is the leader in the 'rSM' (RNA Small Molecule) space, validated by massive deals with Amgen ($75M upfront) and Roche. They are turning RNA biology into a chemistry problem, which allows them to use traditional oral pills rather than complex injections."

✅ Pros

  • ["Pharma Validation: Amgen and Roche deals worth billions in potential bio-bucks.","Oral Delivery: Unlike Moderna/BioNTech (injections), Arrakis creates oral pills, which is a massive commercial advantage.","Leadership: CEO Michael Gilman is a serial biotech winner (Padlock, Stromedix)."]

⚠️ Risks

  • ["Scientific Risk: RNA-small molecule binding is notoriously difficult and prone to off-target effects.","Early Stage: Despite hype, still largely in discovery/preclinical phase with no approved assets."]

🛠️ Use Cases

Market Maturity

Stop Guessing.
Know What's Deployable.

Marketing brochures look the same for TRL-3 (Concept) and TRL-9 (Proven) tech. Our radar cuts through the noise, showing you exactly if this innovation has crossed the "Pilot-to-Production" chasm.

9

Commercial Grade

Fully audited operational history. Ready for scale.

6

Prototype / Pilot

Functional in relevant environments. High risk, high reward.

Current Maturity Status

TRL Score 5.0 / 9.0
  • check_circle Technology validated in lab (TRL 4)
  • check_circle System prototype demonstration (TRL 7)
  • pending Operational Verification (In Progress)
Transparency

Forensic Evidence Chain

We don't just "approve" listings. We build a permanent, immutable audit trail for every verified claim. See exactly what was checked, when, and by whom.

View Sample Audit Report →

Technical Diligence

> Architecture Review: PASS
> Security Audit: ISO 27001
> Scalability Test: 10k TPS

Customer Verification

> Client Interview: #8821
> Deployment Status: LIVE
> ROI Confirmed: 18% Savings

Certification Issued

STATUS: VERIFIED verified

Enterprise Action Center

Select the engagement model that fits your business needs.

🚀
Launch Pilot / POC
Submit your problem statement and request a proof of concept scope.
💡
Propose Use Case
Have a new application for this tech? Submit a use case for review.
⭐
Submit Review
Already using this solution? Verify impact and submit your CSAT score.
🛡️
Request Due Diligence
Access compliance certs, security audits, and financial health reports.

Secure Premium Access

Complete to proceed with your request